Research

Energy balance

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 receptor agonists within the context of randomized controlled trials.

Healthcare providers can continue to prescribe GLP-1 RAs without heightened concern for suicidality in clinical settings.

StrongRefutesmedium confidence
There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 RAs within the context of RCTs.
Pouya Ebrahimi et al. · JAMA Psychiatry · 2025

Why this rating

Based on the systematic review of randomized clinical trials.

Source

Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity

Pouya Ebrahimi et al. · JAMA Psychiatry · 2025

DOI 10.1001/jamapsychiatry.2025.0091

rct · n=59396Cited 29×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →